Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05472168
Other study ID # Timper_Olfactory_2022
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 18, 2022
Est. completion date October 30, 2024

Study information

Verified date December 2023
Source University Hospital, Basel, Switzerland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this preliminary short-term study it is investigated, whether a short olfactory stimulation with distinct odours impacts energy expenditure in patients with obesity and lean patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 58
Est. completion date October 30, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - • Age 18-55 years - Obesity (BMI =30 kg/m2) and Lean (BMI 18-25 kg/m2) - Written informed consent - Normosmia (defined by sniffing Sticks test) Exclusion Criteria: - • Chronic or acute sinusitis - Surgical intervention of the nasal cavity or the paranasal sinus - Known allergy to odors used in the study - Smokers - Current illicit drug abuse including daily marijuana and cannabidiol (CBD) consumption (alcohol =2 drinks per day allowed) - Any kind of severe chronic disease (e.g. severe heart failure, active cancer disease) - Diabetes mellitus - Treatment with insulin sensitizing drugs including Glucagon-like Peptide (GLP)-1 analogues within the last 3 months - History of neurodegenerative diseases, severe head trauma - Severe renal impairment (e.g. estimated glomerular filtration rate <30 ml/min/m2) - Known liver cirrhosis or other severe liver impairment - Use of any kind of decongestant more than twice a week - Use of cortisone-containing nasal spray within the last 3 months - Acute upper respiratory tract infection - Uncontrolled dysthyroidism - Uncontrolled hypertension - Regular use of psychopharmaceutic drugs - Study participants aims to start a new diet or exercise program during the study - Bariatric surgery - Pregnancy/Lactation - Onset of climacteric symptoms within one year (e.g. hot flashes and/or diaphoresis) OR initiation of hormonal replacement therapy in the last three months - Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. - Participation in an interventional study within the last 3 months

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Olfactory Stimulation
Participants are exposed to different odours and energy expenditure is assessed via indirect calorimetry.

Locations

Country Name City State
Switzerland University Hospital Basel Basel

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Energy Expenditure change in energy expenditure as assessed via calorimetry after olfactory stimulation with different odours. 6 hours
Secondary Energy Expenditure, Additional Odours Change in energy expenditure as assessed via calorimetry after olfactory stimulation with Different odours 6 hours
Secondary Heart Rate change in heart rate variability upon olfactory stimulation with different odors as assessed via continuous ECG 6 hours
Secondary Blood Pressure Change in blood pressure upon olfactory stimulation with different odors as assessed via a blood pressure cuff at the upper arm according to Riva Rocci 6 hours
Secondary Metabolic Parameters Change in metabolic blood parameters upon acute olfactory stimulation with different odours 6 hours
Secondary Glucose Levels change in interstitial fluid glucose levels upon olfactory stimulation with different odours 6 hours
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2